MCID: ERY036
MIFTS: 49

Erythema Nodosum

Categories: Genetic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Erythema Nodosum

MalaCards integrated aliases for Erythema Nodosum:

Name: Erythema Nodosum 12 73 54 15 32

Classifications:



External Ids:

Disease Ontology 12 DOID:0080750
ICD10 32 L52

Summaries for Erythema Nodosum

Disease Ontology : 12 A panniculitis that is characterized by sudden onset of painful, erythematous, subcutaneous nodules mainly localized to the pretibial areas. Lesions are usually bilateral and symmetrical, ranging from 1 to 5 cm in diameter.

MalaCards based summary : Erythema Nodosum is related to pulmonary sarcoidosis and panniculitis. An important gene associated with Erythema Nodosum is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Thalidomide and Apremilast have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and neutrophil, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 73 Erythema nodosum (EN), is an inflammatory condition characterized by inflammation of the fat cells under... more...

Related Diseases for Erythema Nodosum

Diseases in the Erythema Nodosum family:

Erythema Nodosum, Familial

Diseases related to Erythema Nodosum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 951)
# Related Disease Score Top Affiliating Genes
1 pulmonary sarcoidosis 31.9 TNF IFNG ICAM1 CSF2
2 panniculitis 31.5 TNF IFNG CRP
3 lepromatous leprosy 31.1 VDR TNF MIF IL10 IFNG ICAM1
4 histoplasmosis 31.0 TNF IFNG C3
5 cellulitis 30.9 TNF IL6 CSF2 CRP
6 tuberculoid leprosy 30.8 TNF IL10 IFNG
7 vasculitis 30.7 VCAM1 TNF SELE IL6 ICAM1 CTLA4
8 pyoderma gangrenosum 30.7 TNF NOD2 CXCL8
9 erythema multiforme 30.6 TNF IL6 IFNG ICAM1 CXCL8
10 syphilis 30.5 TNF IL6 IFNG CRP
11 polyarteritis nodosa 30.4 VCAM1 SELE IL6 ICAM1 CRP
12 systemic onset juvenile idiopathic arthritis 30.4 TNF MIF IL6
13 diverticulitis 30.4 TNF IL6 CRP
14 skin sarcoidosis 30.4 TNF IFNG CTLA4
15 infective endocarditis 30.4 TNF IL6 CRP
16 mixed connective tissue disease 30.4 TNF IL6 IL10 IFNG
17 glomerulonephritis 30.4 VCAM1 MIF IL1B ICAM1 C3
18 neutrophilia, hereditary 30.4 IL6 CSF2 CRP
19 sarcoidosis 1 30.4 TNF NOD2 MIF LTA IL1B IL1A
20 pemphigoid 30.3 TNF IL13 IFNG
21 epidemic typhus 30.3 TNF IL10 CRP
22 pustulosis of palm and sole 30.3 TNF CXCL8 CRP
23 mastitis 30.3 SELE NOD2 IL6 ICAM1 CXCL8 CSF2
24 pulmonary tuberculosis 30.3 VDR TNF IL6 IL10 IFNG C3
25 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.3 IL10 IFNG CTLA4
26 crescentic glomerulonephritis 30.3 VCAM1 SELE ICAM1
27 lymphopenia 30.3 IL6 IL10 IFNG CTLA4
28 anterior scleritis 30.3 TNF CRP
29 hypersensitivity vasculitis 30.3 TNF IL6 CRP C3
30 lymph node tuberculosis 30.3 TNF IFNG CRP
31 echinococcosis 30.3 TNF IL6 IL10 IFNG
32 mycobacterium tuberculosis 1 30.2 VDR TNF NOD2 IL10 IFNG
33 granulomatous hepatitis 30.2 TNF CTLA4 CRP
34 acute myocarditis 30.2 TNF IL10 CRP
35 neutrophilic dermatosis, acute febrile 30.2 TNF IL1B CXCL8 CRP
36 purpura 30.2 TNF IL6 IL10 IFNG CRP C3
37 scleritis 30.2 TNF SELE IFNG CTLA4 CRP
38 systemic autoimmune disease 30.2 IL6 CRP
39 spondyloarthropathy 1 30.2 TNF NOD2 IL6 CRP
40 tuberculous peritonitis 30.2 IFNG CRP
41 cryopyrin-associated periodic syndrome 30.2 IL6 CRP
42 cholera 30.2 TNF IL6 IL1B IL10
43 iridocyclitis 30.1 TNF IL6 IL1B IL10 CRP
44 iritis 30.1 TNF NOD2 IL6 IL10 CRP
45 polymyositis 30.1 VCAM1 IL1A ICAM1
46 rapidly progressive glomerulonephritis 30.1 ICAM1 CRP C3
47 pancreatitis 30.1 TNF IL6 IL1B CRP
48 rheumatic fever 30.1 TNF IL6 IL1A IL10 IFNG ICAM1
49 pyoderma 30.1 TNF NOD2 IL1B CXCL8 CRP
50 severe cutaneous adverse reaction 30.1 TNF CTLA4 CRP

Graphical network of the top 20 diseases related to Erythema Nodosum:



Diseases related to Erythema Nodosum

Symptoms & Phenotypes for Erythema Nodosum

GenomeRNAi Phenotypes related to Erythema Nodosum according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 CXCL8 IL10 IL1A IL1B LTA TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 CXCL8 ICAM1 IL10 IL1B LTA NOD2
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.47 ICAM1

MGI Mouse Phenotypes related to Erythema Nodosum:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.46 C3 CRBN CRP CSF2 CTLA4 ICAM1
2 hematopoietic system MP:0005397 10.45 C3 CRBN CSF2 CTLA4 ICAM1 IFNG
3 homeostasis/metabolism MP:0005376 10.45 C3 CRBN CRP CSF2 CTLA4 ICAM1
4 immune system MP:0005387 10.43 C3 CRBN CRP CSF2 CTLA4 ICAM1
5 growth/size/body region MP:0005378 10.39 C3 CRBN CSF2 ICAM1 IFNG IL10
6 cellular MP:0005384 10.36 C3 CSF2 ICAM1 IFNG IL10 IL13
7 digestive/alimentary MP:0005381 10.28 C3 CRBN CTLA4 ICAM1 IFNG IL10
8 mortality/aging MP:0010768 10.27 C3 CRBN CSF2 CTLA4 ICAM1 IFNG
9 endocrine/exocrine gland MP:0005379 10.26 C3 CSF2 CTLA4 ICAM1 IFNG IL10
10 integument MP:0010771 10.21 CSF2 CTLA4 ICAM1 IFNG IL10 IL13
11 liver/biliary system MP:0005370 10.06 C3 CRBN CTLA4 IFNG IL10 IL6
12 nervous system MP:0003631 9.97 C3 CRBN CSF2 ICAM1 IFNG IL10
13 muscle MP:0005369 9.92 C3 ICAM1 IFNG IL10 IL13 IL6
14 neoplasm MP:0002006 9.91 CSF2 ICAM1 IFNG IL10 IL1A IL1B
15 respiratory system MP:0005388 9.61 CSF2 CTLA4 IFNG IL10 IL13 IL6
16 skeleton MP:0005390 9.4 C3 CSF2 CTLA4 IFNG IL10 IL13

Drugs & Therapeutics for Erythema Nodosum

Drugs for Erythema Nodosum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
2
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
3 Immunologic Factors Phase 4
4 Antirheumatic Agents Phase 4
5 Immunosuppressive Agents Phase 4
6 Anti-Inflammatory Agents Phase 4
7 Angiogenesis Inhibitors Phase 4
8 Analgesics, Non-Narcotic Phase 4
9 Analgesics Phase 4
10 Anti-Bacterial Agents Phase 4
11 Anti-Inflammatory Agents, Non-Steroidal Phase 4
12 Anti-Infective Agents Phase 4
13
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
14
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
15
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
16
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
17
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
18
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
19
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
20
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
21 Methylprednisolone Acetate Phase 2
22 Hormone Antagonists Phase 2
23 glucocorticoids Phase 2
24 Hormones Phase 2
25 Antineoplastic Agents, Hormonal Phase 2
26 Dermatologic Agents Phase 2
27 Cyclosporins Phase 2
28 Calcineurin Inhibitors Phase 2
29 Antifungal Agents Phase 2
30
Montelukast Approved 158966-92-8 5281040
31
Methotrexate Approved 1959-05-2, 59-05-2 126941
32
Levoleucovorin Approved, Investigational 68538-85-2 149436
33
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
34 Respiratory System Agents
35 Anti-Asthmatic Agents
36 Leukotriene Antagonists
37 Vitamin B9
38 Folic Acid Antagonists
39 Folate
40 Vitamin B Complex
41 Antimetabolites

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Pilot Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum Completed NCT04822909 Phase 4 Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet
2 A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only. Completed NCT00919776 Phase 2 prednisolone;ciclosporin
3 A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone. Completed NCT00919542 Phase 2 Ciclosporin;prednisolone
4 A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum Recruiting NCT03807362 Phase 2 CC-11050
5 Montelukast as an Alternative or Supplementary Treatment in ENL Reaction in Leprosy Unknown status NCT00406861 montelukast in treatment of ENL reaction
6 Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum (MaPS in ENL Not yet recruiting NCT03775460 Methotrexate;Placebo;Prednisolone

Search NIH Clinical Center for Erythema Nodosum

Genetic Tests for Erythema Nodosum

Anatomical Context for Erythema Nodosum

MalaCards organs/tissues related to Erythema Nodosum:

40
Skin, T Cells, Neutrophil, Breast, Bone Marrow, Lymph Node, Thymus

Publications for Erythema Nodosum

Articles related to Erythema Nodosum:

(show top 50) (show all 3375)
# Title Authors PMID Year
1
Variation in the lymphotoxin-alpha/tumor necrosis factor locus modifies risk of erythema nodosum in sarcoidosis. 61 54
19225544 2009
2
[Parenteral symptoms and intestinal complications in children with inflammatory bowel diseases in relation to card15 mutation]. 54 61
19305026 2008
3
Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia. 61 54
17964516 2007
4
High expression of myeloid-related proteins 8 and 14 characterizes an inflammatorily active but ineffective response of macrophages during leprosy. 54 61
15056385 2004
5
Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases. 54 61
15190675 2004
6
Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity. 54 61
14613324 2003
7
Differential TNFalpha mRNA regulation detected in the epidermis of leprosy patients. 54 61
12420104 2002
8
Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro. 54 61
11905505 2002
9
Pentoxifylline downregulates nitric oxide and tumor necrosis factor-alpha induced by mycobacterial lipoarabinomannan in a macrophage cell line. 61 54
11875767 2001
10
Tumour necrosis factor-alpha promoter polymorphism in erythema nodosum. 61 54
11411907 2001
11
T cell-monocyte contact enhances tumor necrosis factor-alpha production in response to Mycobacterium leprae. 61 54
11023469 2000
12
Shedding of soluble receptor for tumor necrosis factor alpha induced by M. leprae or LPS from human mononuclear cells. 61 54
10659614 1999
13
Interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) are necessary in the early stages of induction of CD4 and CD8 cytotoxic T cells by Mycobacterium leprae heat shock protein (hsp) 65 kD. 61 54
9822276 1998
14
Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. 61 54
9607928 1998
15
Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). 54 61
9486396 1998
16
Low serum HDL-cholesterol is associated with raised tumor necrosis factor-alpha during ENL reactions. 54 61
9207748 1997
17
Lack of cytotoxic activity against Mycobacterium leprae 65-kD heat shock protein (hsp) in multibacillary leprosy patients. 61 54
7813115 1995
18
Cytokine regulation of disease progression in leprosy and tuberculosis. 54 61
7713571 1994
19
Correlation between TNF production, increase of plasma C-reactive protein level and suppression of T lymphocyte response to concanavalin A during erythema nodosum leprosum. 61 54
8371031 1993
20
In vitro tumor necrosis factor production by mononuclear cells from lepromatous leprosy patients and from patients with erythema nodosum leprosum. 61 54
8500267 1993
21
Tumor necrosis factor production in patients with leprosy. 61 54
1548069 1992
22
Differential expression of the calcium-binding proteins MRP8 and MRP14 in granulomatous conditions: an immunohistochemical study. 54 61
2199095 1990
23
Risk factors of disease activity in patients with Behçet's syndrome. 61
32918637 2021
24
Various skin manifestations related to inflammatory bowel disease: A nationwide cross-sectional study on the Korean population. 61
33608949 2021
25
Drug resistance to rifampicin in a case of steroid-dependent erythema nodosum leprosum and the therapeutic implications of resistance and reactions in leprosy. 61
33811328 2021
26
Patients with idiopathic granulomatous mastitis accompanied by erythema nodosum. 61
33305438 2021
27
A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide. 61
33249990 2021
28
Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multi-ethnic, multicentre cohort. 61
33093118 2021
29
Intravascular large B-cell lymphoma mimicking erythema nodosum: A case report and review of published works. 61
33554355 2021
30
Granulomatous mastitis, erythema nodosum and arthritis syndrome: case-based review. 61
33649961 2021
31
Erythema Nodosum: A Practical Approach and Diagnostic Algorithm. 61
33683567 2021
32
Bilateral leg swelling as the presenting symptom of Löfgren syndrome in a paediatric patient: a rare presentation of a rare paediatric disease. 61
33664030 2021
33
Ciprofloxacin-induced cutaneous adverse drug events: a systematic review of descriptive studies. 61
33725760 2021
34
Unusual non-trophic ulcerations in leprosy: A case series of 17 patients. 61
33722150 2021
35
Increased serum levels of interleukin-6 in erythema nodosum leprosum suggest its use as a biomarker. 61
33769734 2021
36
Using item response theory (IRT) to improve the efficiency of the Simple Clinical Colitis Activity Index (SCCAI) for patients with ulcerative colitis. 61
33752610 2021
37
Juvenile primary Sjogren's syndrome with cutaneous involvement. 61
33712889 2021
38
The Temporal Relationships and Associations between Cutaneous Manifestations and Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study. 61
33810197 2021
39
Association between erythema nodosum/ erythema induratum of Bazin and Mycobacterium tuberculosis infection in Koreans. 61
33666028 2021
40
A rheumatologic approach to granulomatous mastitis: A case series and review of the literature. 61
33523600 2021
41
Investigating the presence of neutrophil extracellular traps in septal and lobular cutaneous panniculitides. 61
33580883 2021
42
Severe type 2 leprosy reaction with COVID-19 with a favourable outcome despite continued use of corticosteroids and methotrexate and a hypothesis on the possible immunological consequences. 61
33326870 2021
43
Recurrent erythema nodosum leprosum associated with Mycobacterium indicus pranii vaccine in a case of leprosy: a rare paradox. 61
33587765 2021
44
Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. 61
33400241 2021
45
A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections. 61
33360321 2021
46
A Case of Whipple Disease With Cutaneous Manifestations. 61
33606378 2021
47
Erythema nodosum-like rash in a COVID-19 patient: A case report. 61
32828595 2021
48
Idiopathic Granulomatous Mastitis and Erythema nodosum - A Unifying Pathophysiology? 61
32935853 2021
49
Erythema nodosum leprosum successfully treated with apremilast: more effective and safer than classic treatments? 61
32970828 2021
50
Erythema nodosum: An uncommon manifestation of Rickettsiosis. 61
33622497 2021

Variations for Erythema Nodosum

Expression for Erythema Nodosum

Search GEO for disease gene expression data for Erythema Nodosum.

Pathways for Erythema Nodosum

Pathways related to Erythema Nodosum according to GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 VCAM1 TNF NOD2 MIF LTA IL6
2
Show member pathways
13.89 TNF LTA IL6 IL1B IL1A IL13
3
Show member pathways
13.8 TNF MIF LTA IL6 IL1B IL1A
4
Show member pathways
13.66 TNF LTA IL6 IL1B IL1A IL13
5
Show member pathways
13.53 TNF LTA IL6 IL1B IL1A IL13
6
Show member pathways
13.48 VCAM1 TNF NOD2 LTA IL6 IL1B
7
Show member pathways
13.43 TNF LTA IL6 IL1B IL1A IL13
8
Show member pathways
13.36 VCAM1 TNF SELE IL6 IL1B IL10
9
Show member pathways
13.07 TNF IL6 IL1B ICAM1 CXCL8 CSF2
10
Show member pathways
12.98 TNF LTA IL6 IL1B IL1A IL13
11
Show member pathways
12.96 TNF IL6 IL1B IL1A IFNG ICAM1
12 12.92 TNF LTA IL6 IL1B IFNG C3
13
Show member pathways
12.84 TNF NOD2 IL6 IL1B IL1A CXCL8
14
Show member pathways
12.79 TNF IL6 IL1B IL1A IL10 IFNG
15
Show member pathways
12.78 TNF LTA IL6 IL1B IL1A
16
Show member pathways
12.78 TNF NOD2 IL6 IL1B IL1A IL13
17
Show member pathways
12.75 TNF LTA IL1B IL1A IFNG
18 12.71 VCAM1 TNF IL1B IL10 IFNG CTLA4
19
Show member pathways
12.68 TNF IL6 IL1B IL10 IFNG
20
Show member pathways
12.54 IL6 IL13 IL10 IFNG CSF2
21
Show member pathways
12.54 TNF IL6 IL1B IL13 IFNG CXCL8
22 12.53 TNF IL1B CXCL8 CSF2 C3
23
Show member pathways
12.5 TNF IL6 IL1B IFNG ICAM1 CRP
24
Show member pathways
12.5 TNF MIF IL6 IL1B IL1A IFNG
25 12.47 TNF LTA IL6 ICAM1 CSF2
26
Show member pathways
12.46 TNF LTA IL6 IL10 CXCL8
27
Show member pathways
12.45 TNF LTA IL6 IL1B IL1A IL13
28
Show member pathways
12.44 TNF IL1B IL1A IL10 IFNG C3
29 12.39 VDR TNF NOD2 IL6 IL1B IL1A
30 12.38 TNF NOD2 IL6 IL1B CXCL8
31 12.38 TNF IL6 IL1B IL1A IL13 IL10
32
Show member pathways
12.34 TNF IL6 IL1A CXCL8
33
Show member pathways
12.34 TNF IL6 IL1B IFNG CXCL8
34
Show member pathways
12.3 TNF IL6 IL1B IL10
35
Show member pathways
12.29 TNF IL1B IL1A IFNG
36 12.29 VCAM1 TNF SELE IL1B IL1A IFNG
37 12.24 TNF IL6 IL1B IL10 CXCL8
38 12.22 VCAM1 SELE ICAM1 CTLA4
39 12.19 TNF MIF IL6 IL1B IL1A IFNG
40 12.16 TNF IL6 IL10 IFNG CSF2
41 12.15 TNF IL1B IL1A IFNG
42 12.15 VCAM1 TNF LTA IL1B ICAM1 CXCL8
43 12.14 VCAM1 TNF SELE NOD2 LTA IL6
44 12.13 TNF IL6 IL1B IL10 IFNG CXCL8
45 12.12 IL6 IL1B IL1A IFNG CXCL8
46 12.11 VCAM1 TNF IL6 IL1B IL1A IL13
47 12.1 VCAM1 TNF SELE IL6 IL1B IL1A
48 12.08 TNF IL6 IL1B IL1A CSF2
49
Show member pathways
12.01 IL6 ICAM1 CXCL8 CSF2
50 12.01 TNF LTA IL1B IL13 IL10 IFNG

GO Terms for Erythema Nodosum

Cellular components related to Erythema Nodosum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TNF MIF LTA IL6 IL1B IL1A
2 external side of plasma membrane GO:0009897 9.65 VCAM1 TNF IL13 ICAM1 CTLA4
3 cell surface GO:0009986 9.63 VCAM1 TNF NOD2 MIF ICAM1 C3
4 extracellular space GO:0005615 9.53 VCAM1 TNF SELE MIF LTA IL6

Biological processes related to Erythema Nodosum according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 10.14 VDR IL6 IL1B IL1A IL10 CXCL8
2 negative regulation of gene expression GO:0010629 10.09 VDR TNF MIF IFNG CXCL8
3 positive regulation of gene expression GO:0010628 10.07 VDR TNF IL6 IL1B IL1A IL13
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.04 TNF NOD2 MIF ICAM1
5 positive regulation of protein phosphorylation GO:0001934 10.03 TNF IL1B IFNG C3
6 leukocyte migration GO:0050900 10.03 TNF SELE MIF ICAM1
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.02 TNF NOD2 IL6 IL1B ICAM1
8 positive regulation of angiogenesis GO:0045766 10.01 IL1B IL1A CXCL8 C3
9 positive regulation of DNA-binding transcription factor activity GO:0051091 9.98 TNF IL6 IL1B IL10
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.96 NOD2 MIF IL6 ICAM1
11 defense response to Gram-positive bacterium GO:0050830 9.96 TNF NOD2 LTA IL6 CRP
12 inflammatory response GO:0006954 9.96 TNF SELE MIF IL6 IL1B IL1A
13 regulation of insulin secretion GO:0050796 9.94 TNF IL6 IL1B IFNG
14 response to nutrient GO:0007584 9.92 VCAM1 NOD2 LTA
15 interferon-gamma-mediated signaling pathway GO:0060333 9.92 VCAM1 IFNG ICAM1
16 cellular response to organic cyclic compound GO:0071407 9.92 TNF NOD2 IL1B
17 positive regulation of interleukin-8 production GO:0032757 9.92 TNF NOD2 IL6 IL1B
18 positive regulation of tumor necrosis factor production GO:0032760 9.92 NOD2 MIF IL6 IL1A IFNG
19 response to lipopolysaccharide GO:0032496 9.92 VCAM1 SELE NOD2 LTA IL1B IL13
20 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.91 TNF NOD2 IL1B
21 response to glucocorticoid GO:0051384 9.91 TNF IL6 IL10
22 positive regulation of interferon-gamma production GO:0032729 9.91 TNF LTA IL1B
23 positive regulation of T cell proliferation GO:0042102 9.91 VCAM1 IL6 IL1B
24 humoral immune response GO:0006959 9.91 TNF LTA IL6 IFNG
25 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.91 TNF IL6 IL13 IFNG CSF2
26 positive regulation of smooth muscle cell proliferation GO:0048661 9.9 TNF IL6 IL13
27 positive regulation of protein complex assembly GO:0031334 9.9 TNF IFNG CRBN
28 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.9 VCAM1 SELE ICAM1
29 positive regulation of interleukin-1 beta production GO:0032731 9.9 TNF NOD2 IL6 IFNG
30 interleukin-12-mediated signaling pathway GO:0035722 9.89 MIF IL10 IFNG
31 positive regulation of chemokine production GO:0032722 9.88 TNF IL6 IFNG
32 positive regulation of nitric oxide biosynthetic process GO:0045429 9.88 TNF IL1B IFNG ICAM1
33 positive regulation of interleukin-6 production GO:0032755 9.88 TNF NOD2 IL6 IL1B IL1A IFNG
34 positive regulation of interleukin-10 production GO:0032733 9.87 NOD2 IL6 IL13
35 negative regulation of endothelial cell apoptotic process GO:2000352 9.87 IL13 IL10 ICAM1
36 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.87 TNF IL1B IL1A CSF2
37 positive regulation of JAK-STAT cascade GO:0046427 9.86 TNF IL6 IL10
38 leukocyte cell-cell adhesion GO:0007159 9.86 VCAM1 SELE ICAM1
39 microglial cell activation GO:0001774 9.86 TNF IL13 IFNG
40 positive regulation of cytokine production GO:0001819 9.85 TNF MIF IL1A IL10 IFNG
41 cytokine-mediated signaling pathway GO:0019221 9.85 VCAM1 TNF IL6 IL1B IL1A IL13
42 negative regulation of neurogenesis GO:0050768 9.84 TNF IL6 IL1B
43 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.84 TNF NOD2 IL6
44 positive regulation of vascular endothelial growth factor production GO:0010575 9.84 IL6 IL1B IL1A C3
45 leukocyte tethering or rolling GO:0050901 9.83 VCAM1 TNF SELE
46 positive regulation of phagocytosis GO:0050766 9.83 TNF NOD2 IL1B IFNG C3
47 positive regulation of immunoglobulin production GO:0002639 9.82 IL6 IL13 IL10
48 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.81 TNF IL1B IFNG
49 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.81 TNF IL1B IL10
50 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.8 TNF IL6 ICAM1

Molecular functions related to Erythema Nodosum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.36 TNF MIF LTA IL6 IL1B IL1A

Sources for Erythema Nodosum

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....